These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 21459808)
1. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Al-Izki S; Pryce G; Jackson SJ; Giovannoni G; Baker D Mult Scler; 2011 Aug; 17(8):939-48. PubMed ID: 21459808 [TBL] [Abstract][Full Text] [Related]
2. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831 [TBL] [Abstract][Full Text] [Related]
3. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice. Wang X; Brieland JK; Kim JH; Chen YJ; O'Neal J; O'Neil SP; Tu TW; Trinkaus K; Song SK NMR Biomed; 2013 Dec; 26(12):1742-50. PubMed ID: 23939596 [TBL] [Abstract][Full Text] [Related]
4. Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen. Yoshida Y; Tsuji T; Fujita T; Kohno T Biol Pharm Bull; 2011; 34(6):933-6. PubMed ID: 21628899 [TBL] [Abstract][Full Text] [Related]
5. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494 [TBL] [Abstract][Full Text] [Related]
6. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Foster CA; Mechtcheriakova D; Storch MK; Balatoni B; Howard LM; Bornancin F; Wlachos A; Sobanov J; Kinnunen A; Baumruker T Brain Pathol; 2009 Apr; 19(2):254-66. PubMed ID: 18540945 [TBL] [Abstract][Full Text] [Related]
7. Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations. Sheridan GK; Dev KK Sci Rep; 2014 May; 4():5051. PubMed ID: 24851861 [TBL] [Abstract][Full Text] [Related]
8. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Balatoni B; Storch MK; Swoboda EM; Schönborn V; Koziel A; Lambrou GN; Hiestand PC; Weissert R; Foster CA Brain Res Bull; 2007 Oct; 74(5):307-16. PubMed ID: 17845905 [TBL] [Abstract][Full Text] [Related]
9. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. Chiba K Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408 [TBL] [Abstract][Full Text] [Related]
10. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127 [TBL] [Abstract][Full Text] [Related]
11. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428 [TBL] [Abstract][Full Text] [Related]
13. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Rausch M; Hiestand P; Foster CA; Baumann DR; Cannet C; Rudin M J Magn Reson Imaging; 2004 Jul; 20(1):16-24. PubMed ID: 15221804 [TBL] [Abstract][Full Text] [Related]
14. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Chun J; Hartung HP Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941 [TBL] [Abstract][Full Text] [Related]
16. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. Chiba K Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007 [TBL] [Abstract][Full Text] [Related]
17. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Hiestand PC; Rausch M; Meier DP; Foster CA Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311 [TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis. Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885 [TBL] [Abstract][Full Text] [Related]